Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy.
Join NEJM Catalyst for the final free virtual event in our 4-part series on the future of #HealthCareDelivery, Clinicians in 2030. This event brings focus back to the heart of care delivery - clinicians - and explains changes that must occur. #NEJMCatLive
This Sounding Board article discusses the absence of data to support the current widespread use of preimplantation genetic testing for aneuploidy as an example of a broader concern in reproductive medicine.
Osteosarcoma is generally treated with resection and adjuvant chemotherapy. Detection of gene rearrangements, copy-number variations, and targeted disruption of tumor suppressors by whole-genome sequencing has not yet led to improved treatment.
This trial compared preimplantation genetic testing for aneuploidy with conventional IVF in women with a good prognosis. The conventional-IVF group had a cumulative live-birth rate that was noninferior to that after PGT-A at 1 year.
CMS is considering whether and under what circumstances Medicare will pay for aducanumab for Alzheimer’s disease. A restrictive coverage determination could save the federal government money, but it would also shift costs to states.